{
    "clinical_study": {
        "@rank": "102759", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating\n      women who have recurrent, stage III, or stage IV endometrial cancer."
        }, 
        "brief_title": "Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer", 
        "condition": "Endometrial Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Endometrial Neoplasms", 
                "Sarcoma, Endometrial Stromal"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the antitumor activity and safety of doxorubicin HCl liposome in patients\n           with advanced or recurrent endometrial cancer.\n\n        -  Determine the response rate, response duration, and overall survival of these patients\n           treated with this regimen.\n\n      OUTLINE: Patients receive doxorubicin HCl liposome IV over 1 hour. Courses repeat every 4\n      weeks in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months for 2 years and then every 6 months for 3 years.\n\n      PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed stage III, IV, or recurrent endometrial carcinoma for which\n             curative radiotherapy or surgery is not an option\n\n          -  Bidimensionally measurable disease\n\n               -  Irradiated field as only site allowed if evidence of progression since\n                  radiotherapy\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Performance status:\n\n          -  GOG 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  SGOT no greater than 3 times ULN\n\n          -  Alkaline phosphatase no greater than 3 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN\n\n        Cardiovascular:\n\n          -  LVEF normal by cardiac echocardiogram or MUGA\n\n        Other:\n\n          -  No concurrent active infection\n\n          -  No prior or concurrent malignancy within past 5 years except nonmelanoma skin cancer\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Prior chemotherapy as radiosensitizer allowed\n\n          -  No prior chemotherapy for advanced or metastatic disease\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  Recovered from prior radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  Recovered from prior surgery\n\n        Other:\n\n          -  No prior therapy that would preclude study\n\n          -  No other concurrent antineoplastic agents\n\n          -  No other concurrent investigational agents"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005861", 
            "org_study_id": "CDR0000067891", 
            "secondary_id": "GOG-0086M"
        }, 
        "intervention": {
            "intervention_name": "pegylated liposomal doxorubicin hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "keyword": [
            "stage III endometrial carcinoma", 
            "stage IV endometrial carcinoma", 
            "recurrent endometrial carcinoma"
        ], 
        "lastchanged_date": "June 7, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/GOG-0086M"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Chao Family Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202-5289"
                    }, 
                    "name": "Indiana University Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242-1009"
                    }, 
                    "name": "Holden Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "New England Medical Center Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39216-4505"
                    }, 
                    "name": "University of Mississippi Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157-1082"
                    }, 
                    "name": "Comprehensive Cancer Center at Wake Forest University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210-1240"
                    }, 
                    "name": "Arthur G. James Cancer Hospital - Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Brookview Research, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma", 
        "overall_official": [
            {
                "affiliation": "Gynecologic Oncology Network", 
                "last_name": "Howard D. Homesley, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Washington University Siteman Cancer Center", 
                "last_name": "Paula M. Fracasso, MD, PhD"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005861"
        }, 
        "results_reference": {
            "PMID": "15975638", 
            "citation": "Homesley HD, Blessing JA, Sorosky J, Reid G, Look KY. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Aug;98(2):294-8."
        }, 
        "source": "Gynecologic Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Gynecologic Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2002"
    }, 
    "geocoordinates": {
        "Arthur G. James Cancer Hospital - Ohio State University": "39.961 -82.999", 
        "Brookview Research, Inc.": "36.166 -86.784", 
        "Chao Family Comprehensive Cancer Center": "33.788 -117.853", 
        "Comprehensive Cancer Center at Wake Forest University": "36.1 -80.244", 
        "Duke Comprehensive Cancer Center": "35.994 -78.899", 
        "Holden Comprehensive Cancer Center": "41.661 -91.53", 
        "Indiana University Cancer Center": "39.769 -86.158", 
        "New England Medical Center Hospital": "42.358 -71.06", 
        "University of Mississippi Medical Center": "32.299 -90.185", 
        "Washington University School of Medicine": "38.627 -90.199"
    }
}